Results 271 to 280 of about 1,262,540 (308)
Some of the next articles are maybe not open access.

Population kinetics of progression free survival (PFS).

Journal of Clinical Oncology, 2019
e18251 Background: We assessed drug type impact on whether PFS curves could be fit by 2 phase decay models on nonlinear regression analysis (NLRA). Methods: We digitized 894 published PFS curves for incurable cancers. We used GraphPad Prism 7 for 1 phase and 2 phase decay NLRA, with constraints Y0 = 100 and plateau = 0. We defined curves as fitting 2
David J. Stewart   +8 more
openaire   +1 more source

Mitotic Index and Progression-Free Survival in Atypical Meningiomas

World Neurosurgery, 2020
Extent of resection and tumor grade are considered the most important predictors of progression-free survival (PFS) in meningiomas. However, adjuvant therapy for atypical meningiomas remains controversial, with variable PFS rates of up to 40%. The current mitotic index (MI) range for atypical meningiomas is broad, comprising all tumors with >4 and
Ricardo A. Domingo   +5 more
openaire   +2 more sources

Sensitivity analysis of progression‐free survival with dependent withdrawal

Statistics in Medicine, 2008
AbstractWe develop a sensitivity analysis method for comparing treatment‐specific distributions where the endpoint is progression‐free survival (PFS). The censoring process may be informative due to selective patient withdrawal, which occurs whenever disease evaluation has been discontinued without progression being documented. The sensitivity analysis
Ping K, Ruan, Robert J, Gray
openaire   +2 more sources

Elacestrant Prolongs Progression-Free Survival in Advanced Breast Cancer

Cancer Discovery, 2022
Abstract Prolonged progression-free survival was seen with elacestrant versus standard-of-care endocrine therapy.
openaire   +2 more sources

Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study

Therapeutic Innovation & Regulatory Science, 2013
This study evaluated the circumstances under which the observed progression-free survival (PFS) benefit may translate into an overall survival (OS) benefit.A simulation study, based on PFS and OS joint model decomposition, was conducted to evaluate the impact of crossover rates, survival post progression (SPP) lengths, and magnitudes of difference in ...
Lijun, Zhang   +3 more
openaire   +2 more sources

Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer

Journal of Clinical Oncology, 2007
Purpose The traditional end point for assessing efficacy of first-line chemotherapies for advanced cancer is overall survival (OS), but this end point requires prolonged follow-up and is potentially confounded by the effects of second-line therapies. We investigated whether progression-free survival (PFS) could be considered a valid surrogate for OS in
Marc, Buyse   +8 more
openaire   +2 more sources

Health insurance status and cancer stage at diagnosis and survival in the United States

Ca-A Cancer Journal for Clinicians, 2022
Jingxuan Zhao   +2 more
exaly  

Home - About - Disclaimer - Privacy